WO2023217184A3 - Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use - Google Patents
Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use Download PDFInfo
- Publication number
- WO2023217184A3 WO2023217184A3 PCT/CN2023/093248 CN2023093248W WO2023217184A3 WO 2023217184 A3 WO2023217184 A3 WO 2023217184A3 CN 2023093248 W CN2023093248 W CN 2023093248W WO 2023217184 A3 WO2023217184 A3 WO 2023217184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted pyridine
- pyrimidine derivative
- preparation
- pharmaceutical composition
- drug
- Prior art date
Links
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003222 pyridines Chemical class 0.000 title abstract 3
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- -1 pyrimidine compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to a substituted pyridine or pyrimidine derivative and a use thereof. Specifically, provided are a substituted pyridine or pyrimidine compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which can be used for preparing a drug, and particularly for preparing a drug for preventing and/or treating a p38 MAPK/MK2 pathway-mediated disease or disorder. Each group in formula (I) is as defined in the description.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210533240.2 | 2022-05-12 | ||
| CN202210533240 | 2022-05-12 | ||
| CN202211139876.5 | 2022-09-19 | ||
| CN202211139876 | 2022-09-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023217184A2 WO2023217184A2 (en) | 2023-11-16 |
| WO2023217184A3 true WO2023217184A3 (en) | 2023-12-28 |
Family
ID=88729709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2023/093248 WO2023217184A2 (en) | 2022-05-12 | 2023-05-10 | Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN117800948A (en) |
| WO (1) | WO2023217184A2 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130143906A1 (en) * | 2011-12-06 | 2013-06-06 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| CN103391718A (en) * | 2010-12-06 | 2013-11-13 | 汇合生命科学股份有限公司 | Substituted pyridinone-pyridinyl compounds |
| WO2022212489A1 (en) * | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| CN116396274A (en) * | 2022-01-06 | 2023-07-07 | 深圳信立泰药业股份有限公司 | Substituted bipyridone compound and preparation method and application thereof |
| CN116444493A (en) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | Derivative containing double parallel rings, preparation method and application thereof |
-
2023
- 2023-05-10 WO PCT/CN2023/093248 patent/WO2023217184A2/en unknown
- 2023-05-10 CN CN202310523350.5A patent/CN117800948A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103391718A (en) * | 2010-12-06 | 2013-11-13 | 汇合生命科学股份有限公司 | Substituted pyridinone-pyridinyl compounds |
| US20130143906A1 (en) * | 2011-12-06 | 2013-06-06 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| WO2022212489A1 (en) * | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| CN116396274A (en) * | 2022-01-06 | 2023-07-07 | 深圳信立泰药业股份有限公司 | Substituted bipyridone compound and preparation method and application thereof |
| CN116444493A (en) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | Derivative containing double parallel rings, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117800948A (en) | 2024-04-02 |
| WO2023217184A2 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021086833A8 (en) | Small molecule inhibitors of kras g12c mutant | |
| NO327709B1 (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, their use in the preparation of a drug as well as pharmaceutical preparations containing them | |
| BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
| CA2495685A1 (en) | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | |
| MX347544B (en) | Polycyclic lpa1 antagonist and uses thereof. | |
| BG108318A (en) | Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments | |
| NO20071577L (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases | |
| JP2013532729A5 (en) | ||
| NO20076425L (en) | Methods of Treating Drug-Resistant Cancer | |
| WO2009073148A3 (en) | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) | |
| BRPI0911476A2 (en) | pyridazinone glycokinase activating compounds, pharmaceutical composition, use of the compounds, method for treating a disease and / or metabolic disorder and process for preparing the compounds | |
| WO2007041666B1 (en) | Preparation of rosuvastatin | |
| US20070249676A1 (en) | Cyanoguanidine prodrugs | |
| BRPI0408727A (en) | compound, process for preparing same, pharmaceutical composition, method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity, and use of a compound | |
| JP2017533964A5 (en) | ||
| BRPI0511524A (en) | compound or a pharmaceutically acceptable salt thereof, prodrug, method for producing an antibacterial effect on a warm-blooded animal, compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof, use of a compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof, a pharmaceutical composition, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof, or an in vivo hydrolysable ester thereof | |
| NO20022591L (en) | Finely form of (S) -2-ethoxy-3- [4- (2- {4- methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid | |
| JP2019527724A5 (en) | ||
| BR0308108A (en) | Compounds; process for the preparation of compound; pharmaceutical composition comprising the same, use of compounds and method of treatment and prophylaxis of diseases and obesity | |
| SG145570A1 (en) | 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| MX2020013847A (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof. | |
| CA2494601A1 (en) | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes | |
| CA3155875A1 (en) | Sulfo-substituted biaryl compounds or salts thereof and preparation method and use thereof | |
| WO2023217184A3 (en) | Substituted pyridine or pyrimidine derivative, pharmaceutical composition thereof, preparation method, and use | |
| BRPI0511526A (en) | compound, prodrug, method for producing an antibacterial effect on a warm-blooded animal, use of a compound, pharmaceutical composition, and process for preparing a compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23802953 Country of ref document: EP Kind code of ref document: A2 |